Legend Biotech Corp
LEGN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LEGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LEGN
Legend Biotech Corp is a biopharmaceutical company focused on developing and commercializing cell therapies, anchored by its approved CAR-T product CARVYKTI for multiple myeloma, with a pipeline of earlier-stage candidates and a net loss position as of 2025.
Key risk: Accumulated deficit and net losses
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 9 clinical trials for Legend Biotech Corp.
Legend Biotech Corp is a biopharmaceutical company focused on developing and commercializing cell therapies, anchored by its approved CAR-T product CARVYKTI for multiple myeloma, with a pipeline of earlier-stage candidates and a net loss position as of 2025.
- As of 2025-12-31, Legend Biotech reported cash & equivalents of $948.6M, total revenue of $306.5M, and a net loss of $30.8M [sec].
- The company's lead product, CARVYKTI, is approved by the FDA and generates commercial revenue under the Janssen Agreement [sec · filed 2026-08-11].
- As of 2025-12-31, Legend Biotech had an accumulated deficit of $2.0 billion [sec · filed 2026-03-10].
- The company expects existing cash and revenue from operations to fund operations and loan repayments for at least the next 12 months [sec · filed 2026-08-11].
- Capital expenditures were $69.3 million in 2025, primarily for property, plant, equipment, and intangible assets [sec · filed 2026-03-10].
What works
- CARVYKTI is a commercially approved product generating revenue under the Janssen Agreement, providing a recurring revenue stream [sec · filed 2026-08-11].
- The company has a cash position of $948.6M as of 2025-12-31 and expects sufficient liquidity for at least 12 months [sec].
- Legend Biotech has a broad portfolio of earlier-stage product candidates beyond CARVYKTI, offering potential pipeline diversification [sec · filed 2026-08-11].
What to weigh
- The company has an accumulated deficit of $2.0 billion as of 2025-12-31 and continues to report net losses [sec · filed 2026-03-10].
- Future capital requirements depend on uncertain factors including clinical trial costs, regulatory outcomes, and commercial success of CARVYKTI [sec · filed 2026-08-11].
- Earlier-stage product candidates may never generate necessary data or achieve marketing approval or commercial success [sec · filed 2026-08-11].
From the filings
Quoted directly from source documents.
As of 2025-12-31, Legend Biotech had an accumulated deficit of $2.0 billion.
“At December 31, 2025, we had an accumulated deficit of $2.0 billion.”
SEC filings · March 10, 2026
The company expects existing cash and revenue to fund operations for at least 12 months.
“we currently expect our existing cash and cash equivalents, and time deposits as well as revenue that we expect to generate from our operations will provide sufficient resources to meet our operational needs and loan repayment needs for at least the next 12 months.”
SEC filings · August 11, 2026
Capital expenditures were $69.3 million in 2025.
“Our capital expenditures for the years ended December 31, 2025, 2024, and 2023 amounted to $69.3 million, $64.6 million, and $104.0 million, respectively.”
SEC filings · March 10, 2026
The company has a broad portfolio of earlier-stage product candidates.
“In addition to our commercial product CARVYKTI, we have a broad portfolio of earlier-stage product candidates.”
SEC filings · August 11, 2026
Risks & what to watch (4)›
Key risks
- Accumulated deficit and net losses — Accumulated deficit of $2.0B as of 2025-12-31; net loss of $30.8M in 2025 [sec · filed 2026-03-10].
- Dependence on CARVYKTI revenue — Future capital needs depend on CARVYKTI sales under Janssen Agreement; uncertainty in revenue timing [sec · filed 2026-08-11].
- Early-stage pipeline uncertainty — Earlier-stage candidates may fail to generate necessary data or achieve approval or commercial success [sec · filed 2026-08-11].
- Need for additional funding — May require additional capital if revenue or costs deviate; inability to raise funds could harm operations [sec · filed 2025-11-12].
What to watch
- Commercial revenue trends of CARVYKTI and any updates on the Janssen Agreement [sec · filed 2026-08-11].
- Clinical trial progress and regulatory outcomes for earlier-stage product candidates [sec · filed 2026-08-11].
- Cash runway and any changes in capital expenditure plans, especially in the US, EU, and China [sec · filed 2026-03-10].
- Ability to achieve operating profitability, as previously targeted for 2026 [sec · filed 2025-05-13].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Legend Biotech Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Legend Biotech Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
255.2 months
D/E 0.73
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 3 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
189
Total value held
$1.57B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 25,696,740 | $464.9M |
| deerfield management company, l.p. | 7,687,638 | $139.1M |
| suvretta capital management, llc | 7,581,029 | $137.1M |
| hhlr advisors, ltd. | 5,984,550 | $108.3M |
| westfield capital management co lp | 5,763,475 | $104.3M |
| blackrock, inc. | 4,684,543 | $84.7M |
| two sigma investments, lp | 1,890,396 | $34.2M |
| kynam capital management, lp | 1,576,295 | $28.5M |
| state street corp | 1,498,372 | $27.1M |
| goldman sachs group inc | 1,464,112 | $26.5M |
Showing top 10 of 189 institutional holders of Legend Biotech Corp. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 23.4%
- Days to cover
- 7.7
- Shares short
- 16,995,758
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LEGN short interestFrequently asked questions
What is the AI investment thesis for Legend Biotech Corp?
Legend Biotech Corp is a biopharmaceutical company focused on developing and commercializing cell therapies, anchored by its approved CAR-T product CARVYKTI for multiple myeloma, with a pipeline of earlier-stage candidates and a net loss position as of 2025.
Who is the CEO of Legend Biotech Corp?
Mr. Alan S. Bash is the chief executive officer of Legend Biotech Corp (LEGN).
Where is Legend Biotech Corp headquartered?
Legend Biotech Corp (LEGN) is headquartered in Somerset, NJ, United States.
What therapeutic areas does Legend Biotech Corp focus on?
Legend Biotech Corp develops therapies across Oncology, Gene Therapy, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.